TWiV dissects a study of COVID-19 vaccination which shows that the timing of initial rollout affects disease outcomes more substantially than final coverage or degree of socioeconomic disparity, and discovery of a novel cellular defense comprising a nuclease that is activated by poxvirus infection and cleaves a specific tRNA molecule to inhibit protein synthesis.

TWiV reveals how treatment with remdesivir for COVID-19 resolved a chronic poliovirus infection in an immunocompromised patient, and the finding that infection with SARS-CoV-2 leads to an increase in new and preexisting autoantibodies.